Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06200584
Status:
COMPLETED
Last Update Posted:
2024-01-11
First Post:
2023-11-21
Brief Title:
Synergistic Effect of Vitamin E D in Reducing Risk of Effects Associated With Atypical Anti-psychotics
Sponsor:
Dr Rabia Arshad
Organization:
University of Karachi
Study Overview
Official Title:
Synergistic Effect of Vitamin E D in Reducing the Risk of Effects Associated With Atypical Antipsychotics
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Atypical antipsychotic drugs are commonly used to treat psychiatric illnesses but they are significantly associated with side effects including acute dystonia akathisia parkinsonism rigidity and tremor tardive dyskinesia bradycardia hypotension impotence sleepiness seizures severe dreams or nightmares and hyperprolactinaemia Vitamin D and E have been the focus of much research in the past fifteen years which has revealed multiple roles in the development and function of the body According to mounting data from the domains of epidemiology and neuroscience vitamin D and E deficiency have been related to a number of neuropsychiatric issues as well as neurodegenerative diseases Additionally antioxidants like vitamin E help to prevent inflammation and highly reactive oxygen molecules from damaging normal cells The use of vitamin E and D supplements has been suggested to improve the overall outcomes of psychiatric illnesses and neurological diseases However the synergistic effect of vitamins E and D in reducing the risk of the adverse effects associated with atypical antipsychotics and improvement in psychiatric illness is not well understood Therefore this study was designed to investigate the potential synergistic effect of vitamin E and D supplements for reducing the adverse effects associated with atypical antipsychotics
Detailed Description:
Inclusion Criteria
1 Patients using antipsychotic medications such as quetiapine olanzapine or risperidone 3 Participants who are between the ages of 20 - 70 years 3 Both gender patients male and female 4 Patients with no other chronic morbidity
1 Patients using antipsychotic medications such as quetiapine olanzapine or risperidone 3 Participants who are between the ages of 20 - 70 years 3 Both gender patients male and female 4 Patients with no other chronic morbidity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None